Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Imaging Sigma-1 Receptor (S1R) Expression Using Iodine-124-Labeled 1-(4-Iodophenyl)-3-(2-adamantyl)guanidine ([124I]IPAG).

Gangangari KK, Váradi A, Majumdar S, Larson SM, Pasternak GW, Pillarsetty NK.

Mol Imaging Biol. 2019 Jun 4. doi: 10.1007/s11307-019-01369-8. [Epub ahead of print]

PMID:
31165385
2.

A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals.

Sharma SK, Lyashchenko SK, Park HA, Pillarsetty N, Roux Y, Wu J, Poty S, Tully KM, Poirier JT, Lewis JS.

Nucl Med Biol. 2019 Apr;71:32-38. doi: 10.1016/j.nucmedbio.2019.04.005. Epub 2019 May 3.

PMID:
31128476
3.

A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and Beyond.

Taldone T, Wang T, Rodina A, Pillarsetty NVK, Digwal CS, Sharma S, Yan P, Joshi S, Pagare PP, Bolaender A, Roboz GJ, Guzman ML, Chiosis G.

Cold Spring Harb Perspect Biol. 2019 Apr 1. pii: a034116. doi: 10.1101/cshperspect.a034116. [Epub ahead of print]

PMID:
30936118
4.

Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate.

Brand C, Sadique A, Houghton JL, Gangangari K, Ponte JF, Lewis JS, Pillarsetty NVK, Konner JA, Reiner T.

EJNMMI Res. 2018 Aug 28;8(1):87. doi: 10.1186/s13550-018-0437-x.

5.

18F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model.

Grkovski M, Fanchon L, Pillarsetty NVK, Russell J, Humm JL.

EJNMMI Res. 2018 Jun 18;8(1):53. doi: 10.1186/s13550-018-0409-1.

6.

TMSOTf assisted synthesis of 2'-deoxy-2'-[18F]fluoro-β-D-arabinofuranosylcytosine ([18F]FAC).

Gangangari KK, Humm JL, Larson SM, Pillarsetty NVK.

PLoS One. 2018 May 1;13(5):e0196784. doi: 10.1371/journal.pone.0196784. eCollection 2018.

7.

Target engagement imaging of PARP inhibitors in small-cell lung cancer.

Carney B, Kossatz S, Lok BH, Schneeberger V, Gangangari KK, Pillarsetty NVK, Weber WA, Rudin CM, Poirier JT, Reiner T.

Nat Commun. 2018 Jan 12;9(1):176. doi: 10.1038/s41467-017-02096-w.

8.

Pretargeting of internalizing trastuzumab and cetuximab with a 18F-tetrazine tracer in xenograft models.

Keinänen O, Fung K, Pourat J, Jallinoja V, Vivier D, Pillarsetty NK, Airaksinen AJ, Lewis JS, Zeglis BM, Sarparanta M.

EJNMMI Res. 2017 Dec 2;7(1):95. doi: 10.1186/s13550-017-0344-6.

9.

Erratum to: Repeatability of [68Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer.

Osborne JR, Kalidindi TM, Punzalan BJ, Gangangari K, Spratt DE, Weber WA, Larson SM, Pillarsetty NVK.

Mol Imaging Biol. 2017 Dec;19(6):952. doi: 10.1007/s11307-017-1104-8. No abstract available.

PMID:
28695370
10.

Repeatability of [68Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer.

Osborne JR, Kalidindi TM, Punzalan BJ, Gangangari K, Spratt DE, Weber WA, Larson SM, Pillarsetty NVK.

Mol Imaging Biol. 2017 Dec;19(6):944-951. doi: 10.1007/s11307-017-1091-9. Erratum in: Mol Imaging Biol. 2017 Jul 10;:.

11.

In Vitro and In Vivo Comparison of Gemcitabine and the Gemcitabine Analog 1-(2'-deoxy-2'-fluoroarabinofuranosyl) Cytosine (FAC) in Human Orthotopic and Genetically Modified Mouse Pancreatic Cancer Models.

Russell J, Pillarsetty N, Kramer RM, Romesser PB, Desai P, Haimovitz-Friedman A, Lowery MA, Humm JL.

Mol Imaging Biol. 2017 Dec;19(6):885-892. doi: 10.1007/s11307-017-1078-6.

12.

Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine.

Nagarajah J, Le M, Knauf JA, Ferrandino G, Montero-Conde C, Pillarsetty N, Bolaender A, Irwin C, Krishnamoorthy GP, Saqcena M, Larson SM, Ho AL, Seshan V, Ishii N, Carrasco N, Rosen N, Weber WA, Fagin JA.

J Clin Invest. 2016 Nov 1;126(11):4119-4124. doi: 10.1172/JCI89067. Epub 2016 Sep 26.

13.

The epichaperome is an integrated chaperome network that facilitates tumour survival.

Rodina A, Wang T, Yan P, Gomes ED, Dunphy MP, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H, Caldas-Lopes E, Alpaugh M, Corben A, Riolo M, Beattie B, Pressl C, Peter RI, Xu C, Trondl R, Patel HJ, Shimizu F, Bolaender A, Yang C, Panchal P, Farooq MF, Kishinevsky S, Modi S, Lin O, Chu F, Patil S, Erdjument-Bromage H, Zanzonico P, Hudis C, Studer L, Roboz GJ, Cesarman E, Cerchietti L, Levine R, Melnick A, Larson SM, Lewis JS, Guzman ML, Chiosis G.

Nature. 2016 Oct 20;538(7625):397-401. doi: 10.1038/nature19807. Epub 2016 Oct 5.

14.

Copper-64 labeled liposomes for imaging bone marrow.

Lee SG, Gangangari K, Kalidindi TM, Punzalan B, Larson SM, Pillarsetty NVK.

Nucl Med Biol. 2016 Dec;43(12):781-787. doi: 10.1016/j.nucmedbio.2016.08.011. Epub 2016 Aug 27.

15.

Synthesis and evaluation of an (18)F-labeled pyrimidine-pyridine amine for targeting CXCR4 receptors in gliomas.

Demoin DW, Shindo M, Zhang H, Edwards KJ, Serganova I, Pillarsetty NV, Lewis JS, Blasberg RG.

Nucl Med Biol. 2016 Oct;43(10):606-11. doi: 10.1016/j.nucmedbio.2016.05.005. Epub 2016 May 14.

16.

Tetrahydroprotoberberine alkaloids with dopamine and σ receptor affinity.

Gadhiya S, Madapa S, Kurtzman T, Alberts IL, Ramsey S, Pillarsetty NK, Kalidindi T, Harding WW.

Bioorg Med Chem. 2016 May 1;24(9):2060-71. doi: 10.1016/j.bmc.2016.03.037. Epub 2016 Mar 21.

17.

Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71.

Taldone T, Zatorska D, Ochiana SO, Smith-Jones P, Koziorowski J, Dunphy MP, Zanzonico P, Bolaender A, Lewis JS, Larson SM, Chiosis G, Pillarsetty NV.

J Labelled Comp Radiopharm. 2016 Mar;59(3):129-32. doi: 10.1002/jlcr.3369. Epub 2016 Jan 25.

18.

(18)F-Based Pretargeted PET Imaging Based on Bioorthogonal Diels-Alder Click Chemistry.

Meyer JP, Houghton JL, Kozlowski P, Abdel-Atti D, Reiner T, Pillarsetty NV, Scholz WW, Zeglis BM, Lewis JS.

Bioconjug Chem. 2016 Feb 17;27(2):298-301. doi: 10.1021/acs.bioconjchem.5b00504. Epub 2015 Oct 28.

19.

Radioiodinated PARP1 tracers for glioblastoma imaging.

Salinas B, Irwin CP, Kossatz S, Bolaender A, Chiosis G, Pillarsetty N, Weber WA, Reiner T.

EJNMMI Res. 2015 Dec;5(1):123. doi: 10.1186/s13550-015-0123-1. Epub 2015 Sep 4.

20.

Synthesis and evaluation of (18)F-labeled ATP competitive inhibitors of topoisomerase II as probes for imaging topoisomerase II expression.

Daumar P, Zeglis BM, Ramos N, Divilov V, Sevak KK, Pillarsetty N, Lewis JS.

Eur J Med Chem. 2014 Oct 30;86:769-81. doi: 10.1016/j.ejmech.2014.09.019. Epub 2014 Sep 8.

21.

Development of a minimal saponin vaccine adjuvant based on QS-21.

Fernández-Tejada A, Chea EK, George C, Pillarsetty N, Gardner JR, Livingston PO, Ragupathi G, Lewis JS, Tan DS, Gin DY.

Nat Chem. 2014 Jul;6(7):635-43. doi: 10.1038/nchem.1963. Epub 2014 Jun 1.

22.

Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solid-Phase Peptide Synthesis.

Zeglis BM, Emmetiere F, Pillarsetty N, Weissleder R, Lewis JS, Reiner T.

ChemistryOpen. 2014 Apr;3(2):48-53. doi: 10.1002/open.201402000. Epub 2014 Apr 6.

23.

Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor.

Kim TS, Cavnar MJ, Cohen NA, Sorenson EC, Greer JB, Seifert AM, Crawley MH, Green BL, Popow R, Pillarsetty N, Veach DR, Ku AT, Rossi F, Besmer P, Antonescu CR, Zeng S, Dematteo RP.

Clin Cancer Res. 2014 May 1;20(9):2350-62. doi: 10.1158/1078-0432.CCR-13-3033. Epub 2014 Feb 28.

24.

Influence of free fatty acids on glucose uptake in prostate cancer cells.

Andersen KF, Divilov V, Sevak K, Koziorowski J, Lewis JS, Pillarsetty N.

Nucl Med Biol. 2014 Mar;41(3):254-8. doi: 10.1016/j.nucmedbio.2013.12.005. Epub 2013 Dec 17.

25.

(18)F-labeled-bioorthogonal liposomes for in vivo targeting.

Emmetiere F, Irwin C, Viola-Villegas NT, Longo V, Cheal SM, Zanzonico P, Pillarsetty N, Weber WA, Lewis JS, Reiner T.

Bioconjug Chem. 2013 Nov 20;24(11):1784-9. doi: 10.1021/bc400322h. Epub 2013 Nov 7.

26.

Synthesis and evaluation of 18F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter.

Zhang H, Huang R, Pillarsetty N, Thorek DL, Vaidyanathan G, Serganova I, Blasberg RG, Lewis JS.

Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):322-32. doi: 10.1007/s00259-013-2558-9. Epub 2013 Oct 31.

27.

Antilipolytic drug boosts glucose metabolism in prostate cancer.

Andersen KF, Divilov V, Koziorowski J, Pillarsetty N, Lewis JS.

Nucl Med Biol. 2013 May;40(4):524-8. doi: 10.1016/j.nucmedbio.2013.01.008. Epub 2013 Feb 28.

28.

Fluorine-labeled dasatinib nanoformulations as targeted molecular imaging probes in a PDGFB-driven murine glioblastoma model.

Benezra M, Hambardzumyan D, Penate-Medina O, Veach DR, Pillarsetty N, Smith-Jones P, Phillips E, Ozawa T, Zanzonico PB, Longo V, Holland EC, Larson SM, Bradbury MS.

Neoplasia. 2012 Dec;14(12):1132-43.

29.

Tumor-specific targeting with modified Sindbis viral vectors: evaluation with optical imaging and positron emission tomography in vivo.

Stelter L, Tseng JC, Torosjan A, Levin B, Longo VA, Pillarsetty N, Zanzonico P, Meruelo D, Larson SM.

Mol Imaging Biol. 2013 Apr;15(2):166-74. doi: 10.1007/s11307-012-0585-8.

30.

An improved strategy for the synthesis of [¹⁸F]-labeled arabinofuranosyl nucleosides.

Zhang H, Cantorias MV, Pillarsetty N, Burnazi EM, Cai S, Lewis JS.

Nucl Med Biol. 2012 Nov;39(8):1182-8. doi: 10.1016/j.nucmedbio.2012.06.008. Epub 2012 Jul 18.

31.

Efficient (18)F-labeling of large 37-amino-acid pHLIP peptide analogues and their biological evaluation.

Daumar P, Wanger-Baumann CA, Pillarsetty N, Fabrizio L, Carlin SD, Andreev OA, Reshetnyak YK, Lewis JS.

Bioconjug Chem. 2012 Aug 15;23(8):1557-66. doi: 10.1021/bc3000222. Epub 2012 Jul 30.

32.

Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.

Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Gomes DaGama EM, Caldas-Lopes E, Beebe K, Perna F, Hatzi K, Vu LP, Zhao X, Zatorska D, Taldone T, Smith-Jones P, Alpaugh M, Gross SS, Pillarsetty N, Ku T, Lewis JS, Larson SM, Levine R, Erdjument-Bromage H, Guzman ML, Nimer SD, Melnick A, Neckers L, Chiosis G.

Nat Chem Biol. 2011 Sep 25;7(11):818-26. doi: 10.1038/nchembio.670.

33.

In vivo imaging of Bcr-Abl overexpressing tumors with a radiolabeled imatinib analog as an imaging surrogate for imatinib.

Glekas AP, Pillarsetty NK, Punzalan B, Khan N, Smith-Jones P, Larson SM.

J Nucl Med. 2011 Aug;52(8):1301-7. doi: 10.2967/jnumed.110.085050. Epub 2011 Jul 15.

34.

The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer.

Zeglis BM, Pillarsetty N, Divilov V, Blasberg RA, Lewis JS.

Nucl Med Biol. 2011 Jul;38(5):683-96. doi: 10.1016/j.nucmedbio.2010.12.008. Epub 2011 Mar 3.

35.

Design and synthesis of a bombesin peptide-conjugated tripodal phosphino dithioether ligand topology for the stabilization of the fac-[M(CO)3]+ core (M=(99 m)Tc or Re).

Kannan R, Pillarsetty N, Gali H, Hoffman TJ, Barnes CL, Jurisson SS, Smith CJ, Volkert WA.

Inorg Chem. 2011 Jul 4;50(13):6210-9. doi: 10.1021/ic200491z. Epub 2011 May 18.

36.

Dosimetry of 18F-labeled tyrosine kinase inhibitor SKI-249380, a dasatinib-tracer for PET imaging.

Dunphy MP, Zanzonico P, Veach D, Somwar R, Pillarsetty N, Lewis J, Larson S.

Mol Imaging Biol. 2012 Feb;14(1):25-31. doi: 10.1007/s11307-010-0462-2.

37.

Optimizing tumor targeting of the lipophilic EGFR-binding radiotracer SKI 243 using a liposomal nanoparticle delivery system.

Medina OP, Pillarsetty N, Glekas A, Punzalan B, Longo V, Gönen M, Zanzonico P, Smith-Jones P, Larson SM.

J Control Release. 2011 Feb 10;149(3):292-8. doi: 10.1016/j.jconrel.2010.10.024. Epub 2010 Nov 1.

38.

Improved synthesis of 2'-deoxy-2'-[18F]-fluoro-1-beta-D-arabinofuranosyl-5-iodouracil ([18F]-FIAU).

Anderson H, Pillarsetty N, Cantorias M, Lewis JS.

Nucl Med Biol. 2010 May;37(4):439-42. doi: 10.1016/j.nucmedbio.2010.01.003. Epub 2010 Mar 6.

39.

(124)I-iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo.

Doubrovin M, Kochetkova T, Santos E, Veach DR, Smith-Jones P, Pillarsetty N, Balatoni J, Bornmann W, Gelovani J, Larson SM.

J Nucl Med. 2010 Jan;51(1):121-9. doi: 10.2967/jnumed.109.066126.

40.

2-18F-Fluoropropionic acid as a PET imaging agent for prostate cancer.

Pillarsetty N, Punzalan B, Larson SM.

J Nucl Med. 2009 Oct;50(10):1709-14. doi: 10.2967/jnumed.109.064212. Epub 2009 Sep 16.

41.

Multimodality imaging of TGFbeta signaling in breast cancer metastases.

Serganova I, Moroz E, Vider J, Gogiberidze G, Moroz M, Pillarsetty N, Doubrovin M, Minn A, Thaler HT, Massague J, Gelovani J, Blasberg R.

FASEB J. 2009 Aug;23(8):2662-72. doi: 10.1096/fj.08-126920. Epub 2009 Mar 26.

42.

Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging.

Dobrenkov K, Olszewska M, Likar Y, Shenker L, Gunset G, Cai S, Pillarsetty N, Hricak H, Sadelain M, Ponomarev V.

J Nucl Med. 2008 Jul;49(7):1162-70. doi: 10.2967/jnumed.107.047324. Epub 2008 Jun 13.

43.

A new acycloguanosine-specific supermutant of herpes simplex virus type 1 thymidine kinase suitable for PET imaging and suicide gene therapy for potential use in patients treated with pyrimidine-based cytotoxic drugs.

Likar Y, Dobrenkov K, Olszewska M, Vider E, Shenker L, Cai S, Pillarsetty N, Hricak H, Ponomarev V.

J Nucl Med. 2008 May;49(5):713-20. doi: 10.2967/jnumed.107.046425. Epub 2008 Apr 15.

44.

Imaging of HSV-tk Reporter gene expression: comparison between [18F]FEAU, [18F]FFEAU, and other imaging probes.

Miyagawa T, Gogiberidze G, Serganova I, Cai S, Balatoni JA, Thaler HT, Ageyeva L, Pillarsetty N, Finn RD, Blasberg RG.

J Nucl Med. 2008 Apr;49(4):637-48. doi: 10.2967/jnumed.107.046227. Epub 2008 Mar 14.

45.

Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.

Veach DR, Namavari M, Pillarsetty N, Santos EB, Beresten-Kochetkov T, Lambek C, Punzalan BJ, Antczak C, Smith-Jones PM, Djaballah H, Clarkson B, Larson SM.

J Med Chem. 2007 Nov 15;50(23):5853-7. Epub 2007 Oct 23.

PMID:
17956080
46.
47.

Imaging herpes viral thymidine kinase-1 reporter gene expression with a new 18F-labeled probe: 2'-fluoro-2'-deoxy-5-[18F]fluoroethyl-1-beta-d-arabinofuranosyl uracil.

Balatoni JA, Doubrovin M, Ageyeva L, Pillarsetty N, Finn RD, Gelovani JG, Blasberg RG.

Nucl Med Biol. 2005 Nov;32(8):811-9.

PMID:
16253805
48.

Design, synthesis, and chemistry of sterically nondemanding primary bisphosphines.

Pillarsetty N, Raghuraman K, Barnes CL, Katti KV.

J Am Chem Soc. 2005 Jan 12;127(1):331-6.

PMID:
15631483
49.

Characterization of supramolecular (H2O)18 water morphology and water-methanol (H2O)15(CH3OH)3 clusters in a novel phosphorus functionalized trimeric amino acid host.

Raghuraman K, Katti KK, Barbour LJ, Pillarsetty N, Barnes CL, Katti KV.

J Am Chem Soc. 2003 Jun 11;125(23):6955-61.

PMID:
12783548
50.

Preclinical tolerance and pharmacokinetic assessment of MU-Gold, a novel chemotherapeutic agent, in laboratory dogs.

Higginbotham ML, Henry CJ, Katti KV, Casteel SW, Dowling PM, Pillarsetty N.

Vet Ther. 2003 Spring;4(1):76-82.

PMID:
12756638

Supplemental Content

Loading ...
Support Center